Austrian Registry on Transjugular Intrahepatic Portosystemic Shunts
Launched by THOMAS REIBERGER · Jan 23, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called the Austrian Registry on Transjugular Intrahepatic Portosystemic Shunts (TIPS), is studying a specific treatment for portal hypertension, a condition that occurs when there is increased pressure in the blood vessels of the liver. The researchers are looking to enroll patients who either have already received or are expected to receive a TIPS procedure. By tracking these patients over time, the study aims to document their health progress and identify certain biological markers that might help predict any complications that could arise from the treatment.
To be eligible for this trial, participants need to be between the ages of 18 and 99, have portal hypertension, and provide informed consent to take part in the study. Once enrolled, participants will be monitored closely, and their health outcomes will be recorded. This trial is currently recruiting participants of all genders, and it offers a valuable opportunity to contribute to the understanding of TIPS and improve future treatments for portal hypertension.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18-99 years
- • Portal hypertension
- • Anticipated or past implantation of a transjugular intrahepatic portosystemic shunt (TIPS)
- • Informed consent
- Exclusion Criteria:
- • Retraction of consent
About Thomas Reiberger
Thomas Reiberger is a distinguished clinical trial sponsor known for his commitment to advancing medical research and improving patient outcomes. With a strong background in clinical pharmacology and a focus on innovative therapeutic solutions, he leads initiatives aimed at evaluating new treatments through rigorous clinical trials. His collaborative approach fosters partnerships with healthcare professionals, research institutions, and regulatory bodies, ensuring the highest standards of safety and efficacy are met. By prioritizing ethical considerations and patient welfare, Thomas Reiberger plays a pivotal role in driving forward the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vienna, , Austria
Patients applied
Trial Officials
Thomas Reiberger, MD
Principal Investigator
Medical University of Vienna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials